Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Air Products and Chemicals, Inc. (APD) - free report >>
Energy Fuels Inc (UUUU) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Air Products and Chemicals, Inc. (APD) - free report >>
Energy Fuels Inc (UUUU) - free report >>
Image: Shutterstock
New Strong Sell Stocks for December 15th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Air Products and Chemicals, Inc. (APD - Free Report) provides atmospheric gases, process and specialty gases, equipment, and services. The Zacks Consensus Estimate for its current year earnings has been revised 6.9% downward over the last 30 days.
Daré Bioscience, Inc. (DARE - Free Report) is a clinical-stage biopharmaceutical company that focuses on developing and marketing women's reproductive health products. The Zacks Consensus Estimate for its current year earnings has been revised 13.2% downward over the last 30 days.
Energy Fuels Inc. (UUUU - Free Report) engages in the extraction, recovery, exploration, and sale of conventional and in situ uranium recovery. The Zacks Consensus Estimate for its current year earnings has been revised 38.9% downward over the last 30 days.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery, development, and delivery of treatments for underserved patient. The Zacks Consensus Estimate for its current year earnings has been revised 2.1% downward over the last 30 days.
CyberArk Software Ltd. (CYBR - Free Report) develops, markets, and sales software-based security solutions and services. The Zacks Consensus Estimate for its current year earnings has been revised 0.6% downward over the last 30 days.
View the entire Zacks Rank #5 List.